{"id":10547,"date":"2026-09-12T11:46:52","date_gmt":"2026-09-12T08:46:52","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=10547"},"modified":"2026-09-12T11:46:52","modified_gmt":"2026-09-12T08:46:52","slug":"chronic-hyperkalemia-in-heart-failure-maintaining-gdmt","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/chronic-hyperkalemia-in-heart-failure-maintaining-gdmt\/","title":{"rendered":"Chronic Hyperkalemia in Heart Failure | Maintaining GDMT"},"content":{"rendered":"<p><span>Chronic Hyperkalemia in Heart Failure | Maintaining GDMT<\/span><\/p>\n<p><span>* Hyperkalemia is a common barrier to optimal RAASi\/ARNI and MRA therapy, particularly in patients with CKD.<\/span><br \/>\n<span>* Reducing or stopping these life-saving therapies because of hyperkalemia may compromise their cardiovascular benefits.<\/span><br \/>\n<span>* Newer potassium binders: patiromer and sodium zirconium cyclosilicate (SZC) can be used to control persistent\/recurrent hyperkalemia and may facilitate continuation or optimization of GDMT.<\/span><br \/>\n<span>* Before chronic treatment, assess reversible causes: medications, potassium supplements, diet, and acidosis.<\/span><br \/>\n<span>* * Monitor K\u207a and renal function; with SZC, also watch for edema due to its sodium content.<\/span><\/p>\n<p><a href=\"https:\/\/reachmd.com\/programs\/cme\/engaging-patients-with-heart-failure-and-chronic-hyperkalemia-shared-decision-making-to-support-guideline-directed-medical-therapy\/37616\/\" target=\"_blank\" data-saferedirecturl=\"https:\/\/www.google.com\/url?q=https:\/\/reachmd.com\/programs\/cme\/engaging-patients-with-heart-failure-and-chronic-hyperkalemia-shared-decision-making-to-support-guideline-directed-medical-therapy\/37616\/&amp;source=gmail&amp;ust=1789284448607000&amp;usg=AOvVaw19x-LgTrKoL5-5rzZ8wLfp\" rel=\"noopener\">https:\/\/reachmd.com\/programs\/<wbr \/>cme\/engaging-patients-with-<wbr \/>heart-failure-and-chronic-<wbr \/>hyperkalemia-shared-decision-<wbr \/>making-to-support-guideline-<wbr \/>directed-medical-therapy\/<wbr \/>37616\/<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Chronic Hyperkalemia in Heart Failure | Maintaining GDMT * Hyperkalemia is a common barrier to optimal RAASi\/ARNI and MRA therapy, particularly in patients with CKD. * Reducing or stopping these life-saving therapies because of hyperkalemia may compromise their cardiovascular benefits. * Newer potassium binders: patiromer and sodium zirconium cyclosilicate (SZC) can be used to control [&hellip;]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-10547","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/10547","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=10547"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/10547\/revisions"}],"predecessor-version":[{"id":10548,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/10547\/revisions\/10548"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=10547"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=10547"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=10547"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}